Have a personal or library account? Click to login
Original paper: A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease Cover

Original paper: A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease

Open Access
|Sep 2018

Abstract

Objective: To evaluate the impact of two original compositions of polyphenols-containing dietary supplement on lipid profile and level of C-reactive protein (CRP) in patients with angiographycally verified coronary artery disease (CAD). Design and methods: 167 patients were selected during their scheduled post-event elective bicycle stress-test examination. All patients received standard CAD therapy and permanent statin therapy and had elevated total cholesterol (TC > 5.0 mmol/L) and/or CRP (>3.5 mg/L) levels. The study consisted of 2 days of polyphenol depletion followed by a 12-week supplementation period in a randomized, blinded, placebo-uncontrolled parallel design. Two different compositions SILVA 1 (Quercetine, linseed oil and Resveratrol), and SILVA 2 (Quercetine, linseed oil and Pycnogenol) were tested. Results: All parameters changed compared baseline and 1 and 3 months in both groups. CRP decreased from 2.48 ± 1.62 mg/L at baseline to 1.97 ± 1.15 mg/L, high density cholesterol (HDL-C) increased from 1.18 ± 0.31 to 1.38 ± 0.34 mmol/L, also decrease of triglycerides (TG) from 1.5 to 1.29 mmol/L after 3 months treatment in SILVA I group was statistically significant (p < 0.001). Changes of parameters between baseline and 1 or 3 months in SILVA II group were not statistically significant. Hovewer, decrease of CRP (from 2.6 ± 1.28 to 2.41 ± 1.68), decrease of low density cholesterol (LDL-C from 2.95 ± 1.2 to 2.88 ± 1.21), increase of HDL-C (from 1.25 ± 0.22 to 1.34 ± 0.23), decrease of TC (from 5.2 ± 1.3 to 5.1 ± 1.28) and decrease of TG (from 1.4 ± 0.41 to 1.3 ± 0.38) can be counted as tendency of changes. Conclusion: This study reveals the superiority of treatment with statins in combination with composition containing Resveratrol for correction of lipid profile and inflamation marker CRP of patients with CAD

Language: English
Page range: 22 - 28
Submitted on: Apr 26, 2018
|
Accepted on: Jun 4, 2018
|
Published on: Sep 1, 2018
Published by: Sciendo
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2018 Kristaps Erglis, Iveta Mintale, Ieva Briede, Aldis Rozenbergs, Sanda Jegere, Inga Narbute, Eriks Jakobsons, Vilnis Dzerve, Martins Erglis, Iveta Bajāre, Andrejs Erglis, published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.